About Sphingolipid delta(4)-desaturase/C4-monooxygenase DES2
Sphingolipid delta(4)-desaturase/C4-monooxygenase DES2 (DEGS2) is a protein
from Homo sapiens identified by UniProt accession
Q6QHC5, 323 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Sphingolipid delta(4)-desaturase/C4-monooxygenase DES2 |
| UniProt accession | Q6QHC5 |
| Gene | DEGS2 |
| Organism | Homo sapiens |
| Length | 323 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (35)
Diseases linked to this target (Open Targets).
- white matter hyperintensity measurement · score 0.43
- pulse pressure measurement · score 0.32
- systolic blood pressure · score 0.30
- blood protein measurement · score 0.30
- caudate nucleus volume · score 0.27
- FEV/FVC ratio · score 0.27
- mean corpuscular volume · score 0.20
- mean corpuscular hemoglobin · score 0.20
- mean corpuscular hemoglobin concentration · score 0.09
- gut microbiome measurement · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6QHC5-F1 | alphafold | PREDICTED | 96.33 | — |
Amino-acid sequence (323 residues)
MGNSASRSDF EWVYTDQPHT QRRKEILAKY PAIKALMRPD PRLKWAVLVL VLVQMLACWL VRGLAWRWLL FWAYAFGGCV NHSLTLAIHD ISHNAAFGTG RAARNRWLAV FANLPVGVPY AASFKKYHVD HHRYLGGDGL DVDVPTRLEG WFFCTPARKL LWLVLQPFFY SLRPLCVHPK AVTRMEVLNT LVQLAADLAI FALWGLKPVV YLLASSFLGL GLHPISGHFV AEHYMFLKGH ETYSYYGPLN WITFNVGYHV EHHDFPSIPG YNLPLVRKIA PEYYDHLPQH HSWVKVLWDF VFEDSLGPYA RVKRVYRLAK DGL
Explore Sphingolipid delta(4)-desaturase/C4-monooxygenase DES2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets